OMSÄTTNING OCH AKTIEKURS
I grafen visas aktiekursutveckling och omsättning för valt bolag. Informationen är fördröjd med 15 min.
- Omsättning
- Aktuell Kurs
- Utvecklingen i dag
Pressreleaser | 24 Jan 2023 | Biosergen
Läs hela nyheten
Biosergen AB: Biosergen - Fungicide…
Biosergen’s drug candidate, BSG005, is undergoing phase 1 studies, and has so far proven to be safe, without toxic effects on the kidneys or liver, something that is common with competing fungicides.…
Pressreleaser | 24 Jan 2023 | Biosergen
Läs hela nyheten
Biosergen AB: Biosergen - Svampdödare…
Biosergens läkemedelskandidat, BSG005 genomgår fas 1-studier och har hittills visat sig säker utan toxisk påverkan på njure eller lever, något som är vanligt hos konkurrerande svampdödande läkemedel. Att få fram…
Pressreleaser | 16 Jan 2023 | Biosergen
Läs hela nyheten
Biosergen AB: Biosergen completes the…
BSG005 is Biosergen’s lead development compound. It is a novel anti-fungal molecule from the group of polyene macrolides known for their broad anti-fungal and fungicidal effect, including on resistant and…
Pressreleaser | 12 Dec 2022 | Biosergen
Läs hela nyheten
Biosergen AB: The first volunteer has…
Biosergen has enrolled the first subjects into the MAD part of the Phase I trial of BSG005. The subjects will be part of a first cohort of total six healthy…
Rapporter | 30 Nov 2022 | Biosergen
Läs hela nyheten
Biosergen AB: Biosergen publishes…
Summary of the Interim Report for Q3 2022 2022 2021 2022 2021 2021TSEK July-Sep July-Sep Jan-Sep Jan-Sep Jan-Dec Other income 493 2.652 3.219 4.653 8.573Profit/loss -14.515 -6.404 -27.496 -24.202 -34.077beforedepreciation(EBITDA)Operating…
Pressreleaser | 20 Oct 2022 | Biosergen
Läs hela nyheten
Biosergen AB: Biosergen's warrants of…
The warrantsThe warrants of series TO2 that was included in the rights issue of units in September 2022, have now been registered at the Swedish Companies Registration Office and the…
Pressreleaser | 19 Oct 2022 | Biosergen
Läs hela nyheten
Biosergen AB: Biosergen allocates shares…
As previously communicated in connection with the Rights Issue, the underwriters, in accordance with the underwriting agreements, had the opportunity to choose to receive underwriting compensation either in the form…
Pressreleaser | 5 Oct 2022 | Biosergen
Läs hela nyheten
Biosergen AB: Biosergen appoints Mangold…
Mangold Fondkommission will fulfil its mandate as a liquidity provider to continuously place trading posts on each buy and sell side in the Biosergen share booklet and ensure that a…
Pressreleaser | 4 Oct 2022 | Biosergen
Läs hela nyheten
Biosergen AB: Biosergen announces the…
Biosergen’s CEO Peder M. Andersen comments:”We are happy with the result of our completed capital raise, which will make Biosergen able to finalise the phase I and initiate the next…
Pressreleaser | 26 Sep 2022 | Biosergen
Läs hela nyheten
Biosergen AB: Mangold Insight publishes…
What can you tell us about Biosergens main candidate BSG005?Can you tell us about the competitors and market opportunities for BSG005?What will the proceeds from the rights issue be used…
Kommande händelser
Ta del av analyser, event och erbjudanden
Prenumerera på nyheter från Erik Penser Bank.
Genom att skicka in din mailadress godkänner du vår personuppgiftspolicy*
Dela nyheter & rapporter från EP Access